TAK-279 (psoriasis drug)

2022: Takeda acquires Nimbus Therapeutics for $6 billion

On December 13, 2022, Takeda entered into an agreement to acquire the allosteric tyrosine kinase 2 (TYK2) inhibitor Nimbus Therapeutics for $6 billion, NDI-034858. Oral therapy is used to treat a variety of autoimmune diseases.

Takeda will pay $4 billion upfront for the drug, which is called NDI-034858 and will be renamed TAK-279, the companies said in a statement. Nimbus is also entitled to two interim payments of $1 billion each if the drug reaches annual net sales of $4 and $5 billion. Evercore acts as Takeda's financial advisor on the deal.

Takeda bought a psoriasis drug business for $6 billion

Psoriasis is a chronic disease with a genetic predisposition, provoked by a number of endo- and exogenous factors, characterized by hyperproliferation and impaired differentiation of epidermal cells. Maturation of such cells normally occurs in 28 days, in people with psoriasis in 4 days. The disease in adults and children manifests as purple-pink with silvery scales. It affects the skin, nails and joints. Globally, about 4% of people experience the condition. There is no age limit for him, but most often occurs between 16 and 22 years old and about 60 years old.

Investors expect growth from Takeda after it absorbed Shire for $62 billion in 2017. Chief Executive Officer Christophe Weber said that the drug provides an opportunity to expand the company's strategy, not limited to Entyvio: a drug for the treatment of ulcerative colitis, which brought about 15% of the company's revenue for the year.

The drug Nimbus inhibits an immune-related protein called tyrosine kinase and has recently yielded positive results in moderate to severe middle-stage psoriasis studies. It is expected to reach the final stage of research in 2023, the statement said.^[1]

Notes